Amphastar Pharmaceuticals (AMPH) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is AMPH's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

RANCHO CUCAMONGA, Calif., Nov. 11, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be participating …

Amphastar Pharmaceuticals, Inc. ( AMPH ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Dan Dischner - Senior Vice President of Human Resources & Corporate Communication William Peters - CFO, Exe…

The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year…

Amphastar Pharmaceuticals NASDAQ: AMPH reported record third-quarter revenue of $207.6 million, up 8% from a year earlier, as sales of BAQSIMI and Primatene MIST and contributions from newer products offset manufacturing…

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.93 per share a year ago.…

Net revenues of $207.6 million for the three months ended September 30, 2026 GAAP net income of $37.8 million, or $0.87 per share, for the third quarter Adjusted non-GAAP net income of $49.3 million, or $1.14 per share, …

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

RANCHO CUCAMONGA, Calif., October 29, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the Company will release results for its third quarter of 2026 ended September 30, 2026, afte…

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and …

Amphastar Pharmaceuticals (NASDAQ: AMPH - Get Free Report) and Enanta Pharmaceuticals (NASDAQ: ENTA - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two compa…

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report) has been given a consensus recommendation of "Reduce" by the eight analysts that are presently covering the firm, MarketBeat.com reports. Two investment an…

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report) EVP Rong Zhou sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an a…

RANCHO CUCAMONGA, Calif., Sept. 1, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be pre…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

